Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$0.28
-$0.09(-6.73%)
At close: 4:00 PM EST
$0.28
-$0.09(-6.73%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous CloseN/A
Volume16.29K
Average Volume (3M)1.63M
Market Cap
$15.34M
Enterprise Value$11.70M
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low reported debt materially reduces near-term solvency and interest-cost risks. This conservative leverage profile preserves strategic optionality to fund clinical programs or negotiate financings over the next several quarters, supporting operational continuity despite losses.
Completed Private Placement TranchesThe executed multi-tranche private placement provided identifiable near-term liquidity, clarifying timing of funds and reducing immediate refinancing pressure. This financing structurally extends runway and supports ongoing R&D activities while aligning new investor interests with governance.
Focused Therapeutic NicheA clear scientific focus on complement system modulation creates deep domain expertise and a defined addressable market in immune-driven diseases. This specialization can produce durable competitive advantages in trial design, regulatory strategy, and partnership appeal if clinical milestones are achieved.
Bears Say
Zero Reported RevenueNo product revenue forces reliance on external capital to fund operations. Persistent operating and net losses erode equity and increase execution risk: without successful clinical progress or partnering, the company will likely require further dilutive financings within the medium term.
Consistent Negative Free Cash FlowSustained negative operating and free cash flow necessitate repeated access to capital markets or partners. Although burn improved from earlier years, the ongoing negative FCF is a structural constraint on program funding pace and increases probability of future dilutive financings over 2-6 months.
Eroding Equity BaseMaterial decline in shareholders' equity reflects cumulative operating losses and weakens the balance-sheet cushion. This deterioration limits flexibility for acquisitions or debt financing and increases dependence on equity raises, raising dilution and governance pressures over the medium term.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $15.34M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 309 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
AKTX Stock 12 Month Forecast
Average Price Target
$27.00
▲(9542.86% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors